<DOC>
	<DOCNO>NCT02915874</DOCNO>
	<brief_summary>The goal study evaluate effectiveness brief , intensive 1-day psychotherapy group intervention ( Acceptance Commitment Therapy , ACT ) , compare 12 week time control group anxiety symptom , vascular function , inflammation , muscle sympathetic nerve activity ( mSNA ) , oxidant stress . Similar measure perform baseline individual low anxiety comparison . Individuals interested study identify online screen survey contact research team ; advertisement , flyer mass email direct individual online screen survey . Those deem eligible participate randomize ACT intervention control group . Assessments anxiety symptom ( via various survey ) vascular function ( via non-invasive , well-established technique ) perform baseline 12 week post-ACT group intervention session . In addition , reassessment anxiety symptom via aforementioned survey take place 6 week post-ACT group session . After 12 week , anxiety vascular assessment repeat re-evaluate severity anxiety symptom , vascular function , inflammation , oxidant stress .</brief_summary>
	<brief_title>Does Treating Anxiety Symptoms With ACT Improve Vascular Inflammation Function ?</brief_title>
	<detailed_description>The investigator hypothesize reduce burden anxiety symptom use Acceptance Commitment Therapy ( ACT ) improve vascular function , inflammation , mSNA , oxidant stress . The investigation also explore secondary endpoint relate oxidant stress inflammation vascular endothelial cell . If anxiety increase inflammation , predict ACT reduce circulate pro-inflammatory cytokine , produce phenotype endothelial cell proteins reflect decrease inflammation compare pre-treatment . And anxiety increase oxidative stress , ACT produce phenotype endothelial cell proteins reflect decrease oxidant stress increase nitric oxide synthase activity .</detailed_description>
	<criteria>Willing able provide write , sign consent nature study explain , prior researchrelated procedure . Age &gt; = 25 &lt; = 65 year age . Healthy , determine health history questionnaire , blood chemistry , 12lead ECG . Blood chemistry indicative normal renal ( creatinine &lt; 2.0mg/dl ) , liver ( &lt; 3 time upper limit ALT , AST ) , thyroid function ( TSH 0.4 5.0 mU/L ) stable thyroid medication dose change 3 month . If currently receive treatment take follow supplement , must willing able discontinue take 2 week prior study visit and/or throughout treatment period : Vitamin C , E multivitamins contain vitamin C E ; omega3 fatty acid ; Phosphodiesterase ( PDE ) 5 inhibitor ( i.e . Viagra® , Cialis® , Levitra® , Revatio® ) ; PDE 3 inhibitor ( e.g. , cilostazol ( Pletal® ) , milrinone , vesnarinone ) . No history cardiovascular disease ( e.g. , heart attack , stroke , heart failure , valvular heart disease , cardiomyopathy ) , peripheral arterial disease . Nonsmokers , define history smoke smoke least past 3 month . Normal rest 12lead ECG ( evidence myocardial infarction , leave ventricular hypertrophy , leftbundle branch block , 2nd 3rd degree AV block , atrial fibrillation/flutter . atherosclerosis ) . Current diagnosis history cancer , liver disease , HIV/AIDS History brain tumor , aneurysm injury Clinical diagnosis mental health disorder bipolar disorder schizophrenia History cardiovascular disease heart angioplasty/stent bypass surgery , myocardial infarction , stroke , heart failure without LV ejection fraction &lt; 40 % , cardiomyopathy , valvular heart disease , cardiomyopathy , heart transplantation , atherosclerosis . Current tobacco user history tobacco use within past 3 month ( cigarette , cigar , chew tobacco , Hookah ) . History lung emphysema , chronic bronchitis chronic obstructive pulmonary disease ( COPD ) . Abnormal rest 12lead ECG ( e.g. , evidence myocardial infarction , leave ventricular hypertrophy , leftbundle branch block , 2nd 3rd degree AV block , atrial fibrillation/flutter , atherosclerosis ) . Serious neurologic disorder include seizure . History renal failure , dialysis kidney transplant . Use investigational product investigational medical device within 30 day prior screen , requirement investigational agent prior completion schedule study assessment . Recent flulike symptom within past 2 week . Pregnant breastfeed screening , plan become pregnant ( self partner ) time study . A urinary pregnancy test do female . If test positive , subject exclude . History rheumatoid arthritis , Grave 's disease , systemic lupus erythamatosis , Wegener 's granulomatosis . Taking anticoagulation , antiseizure , antipsychotic agent . Start dose change antidepressant antianxiety medication within past 3 month ( change medication dose past 3 month , subject eligible ) . Intention start current psychotherapy anxiety and/or depression enrol study . Immunodeficiency systemic autoimmune disease . History bleed disorder condition microcirculation ( i.e . von Willebrand disease , Raynaud 's disease ) . History comorbid condition would limit life expectancy &lt; 1 year . Taking chronic nonsteroidal antiinflammatory drug ( NSAIDs ) aspirin , indomethacin , naproxen , acetaminophen ( Tylenol® ) , ibuprofen ( Advil® , Motrin® ) able willing go 2 week prior study visit . Taking cox2 inhibitor ( Celebrex® , Vioxx® , etc ) allopurinol ( Zyloprim® , Lopurin® , Aloprim® ) . Taking steroids biologics : corticosteroid ( prednisone ) ; methotrexate , infliximib ( Remicade® ) , etaneracept ( Enbrel® ) ; anakinra ( Kineret® ) . Vulnerable population ( prisoner , etc . ) eligible participate study . Current alcohol abuse . On weight loss drug ( i.e . orilistat ( Xenical® ) , sibutramine ( Meridia® ) , phenylpropanolamine ( Acutrim® ) ) , similar overthecounter medication within 3 month screen . Any condition , view PI CoI , place subject high risk poor treatment study compliance .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>